The Pharmaceutical Rivalry Behind the Weight-Loss Drug Boom
Big Take25 Tammi 2024

The Pharmaceutical Rivalry Behind the Weight-Loss Drug Boom

The multi-billion dollar weight-loss drug market has ballooned in the past few years. And the two pharmaceutical companies currently duking it out for market dominance, Novo Nordisk and Eli Lilly, have a century-long rivalry.

Bloomberg News health reporter Madison Muller breaks down how Eli Lilly developed Zepbound, a new drug that can help patients cut more than 20% of their body weight — and why some investors and analysts think it will turn Eli Lilly into the first ever trillion-dollar drug company.

(Corrects characterization of the current size of the weight-loss drug market)

See omnystudio.com/listener for privacy information.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(997)

So Could AI 'Kill Us All'?

So Could AI 'Kill Us All'?

"The people building AI earnestly believe that it could kill us all by the end of the decade." An X post by a former employee of both OpenAI and Anthropic went viral and is prompting big questions. On...

10 Syys 15min

Trump Needs a Win. Enter His Venezuela Oil Deal

Trump Needs a Win. Enter His Venezuela Oil Deal

Oil prices topped $100 per barrel on Wednesday, keeping gas prices and the Iran war at the center of the US midterms conversation. Can President Trump burnish his affordability credentials with what h...

9 Syys 17min

Why the Bond Market Has Everyone On Edge

Why the Bond Market Has Everyone On Edge

The bond market has been grabbing headlines and roiling global markets, particularly in the US and in Japan, where yields are surging and buyer interest remains low. That matters, because as Bloomberg...

8 Syys 16min

Americans Are Spending Billions to Help Their Pets Live Longer

Americans Are Spending Billions to Help Their Pets Live Longer

The wellness and longevity boom has come for a new kind of consumer: your pet. But with clinical trials still underway and questions lingering about the safety and efficacy of off-label drugs and trea...

4 Syys 18min

The Hottest New Trade Is Your Own Electricity

The Hottest New Trade Is Your Own Electricity

Energy consumers are used to a pretty simple transaction with utility companies: get electricity to power your home, pay up every month. Now, more consumers are stockpiling their own energy using sola...

3 Syys 17min

Deadly Flooding in Nepal Highlights Asia’s Climate Vulnerability

Deadly Flooding in Nepal Highlights Asia’s Climate Vulnerability

Hundreds of hydropower workers remain missing in Nepal after a glacial collapse caused catastrophic flooding. The disaster laid bare the rising climate risks across Asia and the danger of building in ...

2 Syys 16min

CIA Director Visits Moscow As Ukraine Stares Down a Dangerous Winter

CIA Director Visits Moscow As Ukraine Stares Down a Dangerous Winter

Russia escalated attacks on the Ukrainian capital of Kyiv this past weekend. It’s the latest signal that Ukraine could face a brutal, decisive winter in this conflict. Meanwhile, the CIA director paid...

1 Syys 14min

TikTok Experimented With Users’ Algorithms. One Died By Suicide

TikTok Experimented With Users’ Algorithms. One Died By Suicide

Meta has agreed to pay a $17 billion settlement over a range of claims related to the safety and privacy of its platforms, including youth use of social media. The outcome, announced last week, could ...

31 Elo 23min

Suosittua kategoriassa Politiikka ja uutiset

uutiscast
vallattomat
aikalisa
politiikan-puskaradio
rss-viihde-media
rss-ootsa-kuullut-tasta
ootsa-kuullut-tasta-2
rss-podme-livebox
otetaan-yhdet
rss-vaalirankkurit-podcast
tervo-halme
rss-voi-venaja
rss-asiastudio
rss-girls-finish-f1rst
rss-raha-talous-ja-politiikka
et-sa-noin-voi-sanoo-esittaa
rikosmyytit
popcorn-with-esko
rss-kaikki-uusiksi
rss-seksicast